BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24457378)

  • 21. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
    Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
    Gao J; Lu M; Yu JW; Li YY; Shen L
    BMC Cancer; 2011 May; 11():177. PubMed ID: 21586171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.
    Schwartzberg LS; Arena FP; Mintzer DM; Epperson AL; Walker MS
    Clin Breast Cancer; 2012 Apr; 12(2):87-93. PubMed ID: 22154117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
    Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
    He MM; Wu WJ; Wang F; Wang ZQ; Zhang DS; Luo HY; Qiu MZ; Wang FH; Ren C; Zeng ZL; Xu RH
    PLoS One; 2013; 8(12):e82798. PubMed ID: 24349363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
    Yu J; Gao J; Lu Z; Li Y; Shen L
    Med Oncol; 2012 Dec; 29(5):3029-34. PubMed ID: 22766748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
    Hu B; Yu JR; Wen ZZ; Shu YQ; Wang BC; Yin HR; Chen L; Bai YX; Liang J; Chen L; Cheng Y; Shen L; Zhou Y; Zhang HG; Li J; Wan DS; Chen S; Jia TZ; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):940-3. PubMed ID: 19173999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of paclitaxel liposome and capecitabine in the treatment of advanced gastric cancer by clinical observation.
    Lu M; Wang T; Wang J
    Int J Clin Pharmacol Ther; 2016 Sep; 54(9):693-7. PubMed ID: 27390051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
    Rosati G; Bilancia D; Germano D; Dinota A; Romano R; Reggiardo G; Manzione L
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi128-32. PubMed ID: 17591806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.
    Luo HY; Xu RH; Wang F; Qiu MZ; Li YH; Li FH; Zhou ZW; Chen XQ
    Chemotherapy; 2010; 56(2):94-100. PubMed ID: 20357440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.
    Kim ST; Kang JH; Lee J; Park SH; Park JO; Park YS; Lim HY; Hwang IG; Lee SC; Park KW; Lee HR; Kang WK
    Eur J Cancer; 2014 Nov; 50(16):2822-30. PubMed ID: 25218337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
    Zhao WY; Chen DY; Qi Q
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.
    Huang H; Han Y; Gao J; Feng J; Zhu L; Qu L; Shen L; Shou C
    Med Oncol; 2013 Dec; 30(4):748. PubMed ID: 24135868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
    Qiu MZ; Wei XL; Zhang DS; Jin Y; Zhou YX; Wang DS; Ren C; Bai L; Luo HY; Wang ZQ; Wang FH; Li YH; Yang DJ; Xu RH
    Tumour Biol; 2014 May; 35(5):4369-75. PubMed ID: 24515655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
    Gao J; He Q; Hua D; Mao Y; Li Y; Shen L
    Clin Transl Oncol; 2013 Aug; 15(8):619-25. PubMed ID: 23263912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.
    Lim T; Lee J; Lee DJ; Lee HY; Han B; Baek KK; Ahn HK; Lee SJ; Park SH; Park JO; Park YS; Lim HY; Kim KM; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):255-62. PubMed ID: 21526353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study.
    Orditura M; Martinelli E; Galizia G; Carlomagno C; Aurilio G; Vecchione L; Lieto E; De Placido S; Catalano G; Ciardiello F; De Vita F
    Ann Oncol; 2006 Oct; 17(10):1529-32. PubMed ID: 16873436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.